on BioNxt Solutions Inc. (CVE:BNXT)
BioNxt Solutions Inc. Extends Convertible Debentures and Issues Warrants
BioNxt Solutions Inc., a bioscience company listed on multiple exchanges including CSE and OTCQB, has announced amendments to its unsecured convertible debentures. The debentures, with a combined principal of several million dollars and an 8% interest rate, were initially set to mature between November 2026 and March 2027. These maturities have now been extended by one year.
As compensation for the extension, BioNxt will issue 16,900,000 common share purchase warrants to debenture holders. Each warrant permits the purchase of a common share for $0.50 within a year of issuance. These transactions await the necessary regulatory approvals.
The issued warrants and any shares derived from them are subject to a hold period as per securities legislation. More details on terms and conditions can be found in previous news releases or on the company's profiles on public platforms.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all BioNxt Solutions Inc. news